UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000002864 |
|---|---|
| Receipt number | R000003494 |
| Scientific Title | Association of HLA-DR gene polymorphism and rheumatoid arthritis associated genes (PADI4 and IRF5 polymorphisms) with juvenile idiopathic arthritis. |
| Date of disclosure of the study information | 2009/12/10 |
| Last modified on | 2010/06/09 09:12:48 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Association of HLA-DR gene polymorphism and rheumatoid arthritis associated genes (PADI4 and IRF5 polymorphisms) with juvenile idiopathic arthritis.
Acronym
Association of HLA-DR gene polymorphism and rheumatoid arthritis associated genes (PADI4 and IRF5 polymorphisms) with juvenile idiopathic arthritis.
Scientific Title
Association of HLA-DR gene polymorphism and rheumatoid arthritis associated genes (PADI4 and IRF5 polymorphisms) with juvenile idiopathic arthritis.
Scientific Title:Acronym
Association of HLA-DR gene polymorphism and rheumatoid arthritis associated genes (PADI4 and IRF5 polymorphisms) with juvenile idiopathic arthritis.
Region
| Japan |
Condition
Condition
juvenile idiopathic arthritis
Classification by specialty
| Pediatrics |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
To evaluate association of HLA-DR gene polymorphism and rheumatoid arthritis associated genes (PADI4 and IRF5 polymorphisms) with juvenile idiopathic arthritis.
Basic objectives2
Others
Basic objectives -Others
pathogenesis
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Prevalence of juvenile idiopathic arthritis
Key secondary outcomes
Subgroup analysis based on (1) subtype of JIA (systemic onset or oligoarticular/polyarticular onset), (2) response to therapy, (3) the level of anti-citrullinated peptide antibodies, rheumatoid factor, antinuclear antibody, or matrix metalloproteiase-3, (4) family history of rheumatic disease and autoimmune disease,(5) complications such as macrophage activation syndrome and uveitis
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| 18 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
The patients with juvenile idiopathic arthritis treated in our hospital and with obtained prior written informed consent from patients and/or their parents.
Key exclusion criteria
The patient judged as improper case for enrollment in this study
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masakatsu Yanagimachi |
Organization
Yokohama City University School of Medicine
Division name
Department of Pediatrics
Zip code
Address
3-9 Fukuura, Kanazawa-ku, Yokohama
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Masakatsu Yanagimachi |
Organization
Yokohama City University School of Medicine
Division name
Department of Pediatrics
Zip code
Address
TEL
045-787-2671
Homepage URL
Sponsor or person
Institute
Department of Pediatrics, Yokohama City University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Health and labour Sciences Research Grants
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2009 | Year | 12 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2009 | Year | 12 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 12 | Month | 01 | Day |
Last follow-up date
| 2010 | Year | 03 | Month | 01 | Day |
Date of closure to data entry
| 2010 | Year | 03 | Month | 01 | Day |
Date trial data considered complete
| 2010 | Year | 06 | Month | 01 | Day |
Date analysis concluded
| 2010 | Year | 06 | Month | 01 | Day |
Other
Other related information
Case-control study
Management information
Registered date
| 2009 | Year | 12 | Month | 09 | Day |
Last modified on
| 2010 | Year | 06 | Month | 09 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003494
